General Nutraceutical Technology, LLC
Briarcliff Manor, NY
- UEI
- TWSCJ6T3LNW7
- CAGE
- 86M80
- Primary NAICS
- 541713 Research and Development in Nanotechnology
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Partnership or Limited Liability Partnership
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 565 N State Rd, Briarcliff Manor, NY 10510, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Moonlight Therapeutics, Inc. | Marietta, GA | — |
| Alerje, Inc. | Kalamazoo, MI | 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| Qrono, Inc. | Pittsburgh, PA | 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| Biotechnology | Temecula, CA | — |
| Larix Bioscience LLC | Sunnyvale, CA | — |
About the company
General Nutraceutical Technology LLC is a New York-based biotechnology startup focused on developing nutraceutical products to treat food allergies. As a minority and woman-owned small business, it has received four prime federal grants from the National Institutes of Health to support research and development of two pipeline products - an anthraquinone compound called xanthopurpurin and a nanoformulation containing the compound berberine.
The grants awarded to General Nutraceutical Technology funded research to assess the efficacy, safety, pharmacokinetics, and mechanisms of action of these compounds in suppressing immunoglobulin E (IgE) production and protecting against anaphylaxis in mouse models of peanut, tree nut, and other food allergies. Specifically, the company received an initial Phase I STTR grant of $225,000 to develop the berberine nanoformulation "NIT-X," followed by a $920,225 Phase II STTR to generate manufacturing and clinical trial data for an Investigational New Drug filing. It also secured two R01 research project grants from the National Institute of Allergy and Infectious Diseases Allergy and Infectious Diseases Research program, totaling over $530,000, to test NIT-X and the xanthopurpurin analog XPP1A in additional allergy models and elucidate mechanisms of action. Through its grant-funded research, General Nutraceutical Technology aims to develop non-food restricted therapeutics for severe, multiple, and cross-reactive food allergies.
Quick answers
Is General Nutraceutical Technology, LLC registered in SAM.gov?
Yes. General Nutraceutical Technology, LLC's SAM.gov registration is active through May 19, 2027.
What is General Nutraceutical Technology, LLC's most recent federal award?
General Nutraceutical Technology, LLC's most recent federal grant award is IGE-suppressing small molecule compound xanthopurpurin analog for multiple food allergies - food allergy (FA), a… (R41AI172572), from National Institute of Allergy and Infectious Diseases (NIH), on July 12, 2023.
On GovTribe
See General Nutraceutical Technology, LLC's full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors